Business Wire

JSR Life Sciences Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA

Share

JSR Life Sciences, LLC (JSR) today announced that Mark W. Womack will serve as the Chief Executive Officer of two of its affiliate companies: KBI Biopharma, a leading global CDMO specializing in drug development and biologics manufacturing, and Selexis SA, an industry-leading cell line development provider. Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the U.S. Womack’s appointment is effective May 2, 2022. He will report to JSR Life Sciences President Tim Lowery.

“Mark’s impressive track record includes extensive CDMO and biologics experience, as well as the ability to deliver overall growth, revenue generation, and organizational alignment,” said Tim Lowery, President, JSR Life Sciences. “His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees. I look forward to working with Mark and his teams as we continue to provide best-in-class capabilities for outsourced drug development and manufacturing services.”

Womack brings a consistent track record of successful leadership and life sciences experience to KBI and Selexis. He most recently served as the CEO and Managing Director of Stelis Biopharma, where he oversaw the development and implementation of the infrastructure for a pure-play CDMO, including an end-to-end biologics offering, across multiple facilities. In 2021, he led the company’s efforts to build and qualify a state-of-the-art vaccine facility capable of clinical and commercial-scale manufacturing in record time.

Prior to Stelis, Womack served as the Chief Business Officer at AGC Biologics, in which his extensive experience driving organizational performance improvements led to a nearly 300% increase in new sales in just two years. His career began with more than ten years of distinguished service in the U.S. Navy, where he was recognized with many of their highest honors for exceptional leadership.

“KBI and Selexis are helping create a world where everyone has access to vital treatments that improve or extend their lives,” said Womack. “I’m honored to join JSR and these two great organizations in their mission to help our clients solve their greatest scientific challenges – in turn, providing life-saving therapeutics to patients across the globe. I look forward to supporting the KBI and Selexis teams’ continued growth trajectory and building on their long commitment to quality and innovation.”

Womack joins KBI and Selexis amid a period of profound expansion for both companies. In April, KBI cut the ribbon on its new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. This will soon be followed by significant European expansion through the opening of a newly scaled, state-of-the-art GMP facility that will co-locate both KBI Biopharma and Selexis SA in Geneva, Switzerland.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com

About KBI Biopharma

KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com.

About Selexis SA

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 155 drug candidates in preclinical and clinical development and the manufacture of nine commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com

Laura Morgan
JSR Life Sciences Media Inquiries
Sam Brown Inc.
lauramorgan@sambrown.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Announces Deeper Collaboration with Appium as Strategic Partnership2.7.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced it has become a strategic sponsor of Appium, the world’s most widely used open-source framework for mobile automation. This collaboration aims to significantly simplify and accelerate mobile test automation by integrating Appium’s capabilities into LambdaTest’s cloud-based distributed testing platform. LambdaTest has an active open-source program that provides access to LambdaTest’s testing infrastructure to community projects, so maintainers can run comprehensive test suites without worrying about servers or setup. The organization had also launched LambdaTest Grants for Open Source to support innovation in software testing frameworks and toolsets. As part of the Grants, LambdaTest had announced a $250,000 grant for open source projects and contributors building solutions for the QA and Testing community. With this Appium Strategic Partnership, LambdaTest is doubling down on the commitment made to the open

IO Interactive Announces Olivier Perbet as Chief Marketing and Revenue Officer2.7.2025 16:00:00 EEST | Press release

IO Interactive, the award-winning developer and publisher behind the globally-acclaimed HITMAN franchise, is proud to announce the promotion of Olivier Perbet to Chief Marketing and Revenue Officer (CMRO). In this expanded role, Olivier will now oversee both marketing and revenue operations across the studio’s portfolio, including Digital and Physical Sales, Business Development, and go-to-market strategy, as IOI enters an exciting new chapter of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702593970/en/ © IO Interactive A/S Olivier joined IO Interactive as Chief Marketing Officer in 2023, bringing with him over 20 years of experience across gaming, consumer electronics, and entertainment. Since then, he has played a key role in scaling IOI’s global publishing capabilities, supporting the set-up of IOI Partners and delivering standout campaigns. Under Olivier’s leadership, IOI recently celebrated major milestone

Seoul Semiconductor’s World’s No.1 Technology Targets EV and Autonomous Vehicle Markets2.7.2025 16:00:00 EEST | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), the world’s No. 1 company in LED backlight, announced on July 2nd that its proprietary No-wire technology, WICOP, has been supplied to the automotive market in the form of Mini LED displays since May. As the world’s first No-wire LED technology, WICOP has already proven its performance across various applications—including smartphones, TVs, lighting, and automotive headlamps. Recognized for its superior brightness and durability even in extreme automotive environments, WICOP has now officially entered the automotive display market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702244031/en/ [Figure] Comparison of 1st-Generation LED and 2nd-Generation ‘WICOP’ Structure (Image: Seoul Semiconductor) The No-wire WICOP technology applied to Mini LED enables ultra-slim display designs, making it ideal for full array local dimming. This allows for deeper contrast and higher bright

Barilla Launches 7th Edition of Good Food Makers to Shape the Future of Food2.7.2025 15:20:00 EEST | Press release

Barilla officially opens applications for Good Food Makers 2025, its open innovation program dedicated to startups and innovative companies focused on creating a more sustainable and connected food system. Now in its seventh edition, the program welcomes a new format — Good Food Makers – ECOSYSTEM — developed in collaboration with Almacube, the innovation hub of the University of Bologna and Confindustria Emilia. This year’s goal is to build a true innovation ecosystem by involving Barilla’s value chain partners and accelerating the adoption of emerging technologies. Three selected startups will join a four-week co-development journey with Barilla professionals and partner companies, working side-by-side to create impactful solutions across the entire food chain — from field to fork. Applications are open until the end of July, with the program running from September to January 2026, concluding with the Innovation Day. “Good Food Makers reflects our commitment to open innovation that g

SE Labs Award Reinforces NetApp Status as the Most Secure Storage on the Planet2.7.2025 15:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it was recognized as a standout performer in cybersecurity in the SE LABS ® Awards 2025. NetApp won the 2025 SE Labs Award for Enterprise Data Protection, validating NetApp’s status as the most secure storage on the planet. This recognition as a winner of a 2025 SE Labs Award is a result of NetApp’s exceptional innovation in cyber resiliency to deliver NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI), which was tested and validated by SE Labs. NetApp ARP/AI demonstrated 99 percent detection of tested, advanced full-file encryption ransomware attacks with zero false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue. “Great security doesn’t just happen—it’s built, tested and proven,” says Simon Edwards, Founder and CEO of SE Labs. “Behind every high performing security product is a team committed to excel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye